Email
Password
To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Or registration with your favorite social network

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

Company

BIODOL THERAPEUTICS

BIODOL THERAPEUTICS_logo
5
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Biodol Therapeutics (BDT) develops first-in-class compounds for the first specific treatment of chronic neuropathic pain (NP).

Montpellier, Occitanie, France

Send a message

  • 3

    employees

English

BIODOL THERAPEUTICS Who are we?

Biodol Therapeutics, a biotech company, aims at developing first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified a specific receptor (FLT3) as a key pain component for triggering and maintaining the chronic neuropathic pain (NP) state. Biodol Therapeutics also discovered that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces the opioid doses while maintaining the opioid efficacy and...

See more

Biodol Therapeutics, a biotech company, aims at developing first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified a specific receptor (FLT3) as a key pain component for triggering and maintaining the chronic neuropathic pain (NP) state. Biodol Therapeutics also discovered that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces the opioid doses while maintaining the opioid efficacy and avoiding its mid-term side effects on CP. The development of molecules, intra- or extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics (5 patents).

Biodol Therapeutics is a well-experienced Team:

Dr. Fabien GRANIER (CEO), 15 years of experience in setting up and managing innovative companies and in managing innovation funding levers;

Dr. Pierre SOKOLOFF (Chairman of the SAB), former director of Exploratory R&D in Neurology-Psychiatry at Pierre Fabre Laboratories;

Dr. Bernard PAU (Business Development), former Director of the Department of Life Sciences of the CNRS;

Prof. Jean VALMIER (SAB), discovered the patented mechanism at Institut des Neurosciences in Montpellier;

Dr. Didier ROGNAN (SAB), Deputy Director of the Laboratory of Therapeutic Innovation in Strasbourg.

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Communities

Communauté SATT
SATTs are Societies By Simplified Actions created by several public research centers as part of the "Investments for the Future" Program (french PIA); within the commercialization department.
169 Members